ReviewFrontiers in oncology2026
Esophageal intramural metastasis from adenocarcinoma of esophagogastric junction: a case report and literature review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intramural metastasis from adenocarcinoma of the esophagogastric junction (AEG) to the esophagus is a rare event and is associated with a poor prognosis. Case summary and literature review: We report a 77-year-old male patient diagnosed with AEG with esophageal intramural metastasis. Upper gastrointestinal endoscopy revealed an infiltrative ulcerative tumor at the esophagogastric junction and a submucosal protrusion in the middle esophagus. Biopsies from both lesions confirmed moderately to poorly differentiated adenocarcinoma. The patient received seven cycles of neoadjuvant chemotherapy (oxaliplatin and tegafur), followed by lower esophagectomy and total gastrectomy. Postoperative radiotherapy was administered for residual esophageal metastasis. Although the patient initially improved, he died approximately three years after surgery. A systematic search of PubMed, Embase, and Web of Science identified six relevant articles on esophageal intramural metastasis from AEG. The findings suggest that tumor cells primarily spread through venous and lymphatic channels within the esophageal wall. The presence of intramural metastasis on endoscopy indicates systemic disease and a poor prognosis. An individualized treatment approach, potentially combining neoadjuvant chemotherapy, radiotherapy, immunotherapy, and surgery, may offer the best outcome. Conclusion: Esophageal intramural metastasis from AEG is a rare but aggressive metastatic pattern. Its detection warrants prompt recognition and a multidisciplinary, individualized treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.